NetEase, Inc. · NTES · FY2025 Q3 · Calendar Q4 2025
NetEase: New launches and overseas growth support Q3 momentum
The supplied analysis supports a constructive but conditional view: new launches, overseas expansion, live-ops and AI may extend growth, but the case depends on execution, flagship-title performance and competitive conditions.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about NTES FY2025 Q3
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Relative to the prior-quarter analysis, the supplied Q3 analysis places more emphasis on overseas performance, AI and live-ops as portfolio differentiators, while highlighting organizational adjustments and a stronger quality-over-quantity development focus.
Guidance delta
No explicit forward guidance was provided in the supplied analysis.
Key takeaways
- Management attributed growth to new launches and strong overseas performance
- AI, live operations and global expansion are central to the strategy
- Management is emphasizing quality and flagship projects while pursuing efficiency
Management priorities
- Execute upcoming global releases, including Sea of Remnants and Ananta
- Continue AI research and integration across development pipelines
- Prioritize high-quality flagship projects and prune underperforming initiatives
Follow NTES with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Nov 10, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | Maintain | Sep 28, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Feb 12, 2026 |
| Benchmark | Buy | Buy | Maintain | Nov 21, 2025 |
| JP Morgan | Overweight | Neutral | Upgrade | Oct 10, 2025 |
| Arete | Buy | Sell | Upgrade | Sep 3, 2025 |
| B of A Securities | Buy | Buy | Maintain | Jan 15, 2025 |
| Citigroup | Buy | Buy | Maintain | Nov 15, 2024 |
| Jefferies | Buy | Buy | Maintain | Aug 22, 2024 |
| HSBC | Buy | Buy | Maintain | Apr 24, 2024 |
| Bernstein | Outperform | Outperform | Maintain | Jun 5, 2023 |
| UBS | Buy | Buy | Maintain | May 26, 2023 |
| 86 Research | Buy | Hold | Upgrade | Feb 25, 2022 |
| Macquarie | Neutral | Neutral | Maintain | May 19, 2021 |
| CLSA | Buy | Buy | Maintain | May 19, 2021 |
| Daiwa Capital | Buy | Buy | Maintain | Aug 14, 2020 |
| Nomura Instinet | Buy | Buy | Maintain | May 21, 2020 |
| Nomura | Buy | Buy | Maintain | May 21, 2020 |
| CFRA | Buy | Buy | Maintain | May 20, 2020 |
| Goldman Sachs | Buy | Neutral | Upgrade | Dec 4, 2019 |
| Citi | Buy | Buy | Maintain | Sep 6, 2019 |
| Bank of America | Buy | Buy | Maintain | Nov 17, 2017 |
| Standpoint Research | Reduce | Buy | Downgrade | Jun 7, 2017 |
| Brean Capital | Buy | Buy | Maintain | Jul 18, 2016 |
| CICC | Buy | Hold | Upgrade | Apr 8, 2015 |
| Credit Suisse | Outperform | Neutral | Upgrade | Oct 21, 2014 |
| China International Capital | Hold | Buy | Downgrade | Aug 12, 2014 |
| TH Capital | Hold | Buy | Downgrade | Feb 10, 2014 |
| Deutsche Bank | Hold | Buy | Downgrade | Nov 15, 2013 |
| Exane BNP Paribas | Buy | Buy | Maintain | Sep 30, 2013 |
| PiperJaffray | Overweight | Overweight | Maintain | Aug 16, 2012 |
| Piper Sandler | Overweight | Overweight | Maintain | Aug 16, 2012 |
| Oppenheimer | Outperform | Outperform | Maintain | Aug 16, 2012 |
| Mirae Asset | Buy | Buy | Maintain | Jul 10, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $129.65. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Yang Liu | $163 | $115.41 | +25.7% | Sep 28, 2026 |
| BNP Paribas | Analyst unavailable | $180 | $117.47 | +38.8% | Sep 22, 2026 |
| Bernstein | Robin Zhu | $160 | $127.38 | +23.4% | Aug 21, 2026 |
| Goldman Sachs | Analyst unavailable | $169 | $129.7 | +30.4% | Jul 1, 2026 |
| Morgan Stanley | Yang Liu | $158 | $123.86 | +21.9% | May 26, 2026 |
| Morgan Stanley | Yang Liu | $154 | $114.62 | +18.8% | Mar 2, 2026 |
| Macquarie | Analyst unavailable | $158 | $118.14 | +21.9% | Feb 12, 2026 |
| Barclays | Analyst unavailable | $132 | $118.46 | +1.8% | Feb 12, 2026 |
| Barclays | Analyst unavailable | $135 | $133.95 | +4.1% | Nov 21, 2025 |
| Bernstein | Analyst unavailable | $155 | $133.95 | +19.6% | Nov 21, 2025 |
| Morgan Stanley | Analyst unavailable | $170 | $149.59 | +31.1% | Oct 8, 2025 |
| Goldman Sachs | Lincoln Kong | $161 | $154.83 | +24.2% | Sep 15, 2025 |
| Arete Research | Zixiao Yang | $150 | $135.71 | +15.7% | Sep 2, 2025 |
| Barclays | Jiong Shao | $120 | $129.22 | -7.4% | Aug 18, 2025 |
| Bernstein | Robin Zhu | $105 | $101.36 | -19.0% | Dec 9, 2024 |
| Barclays | Jiong Shao | $82 | $82.08 | -36.8% | Aug 26, 2024 |
| Jefferies | Thomas Chong | $103 | $82.25 | -20.6% | Aug 22, 2024 |
| Jefferies | Thomas Chong | $216 | $88 | +66.6% | Aug 5, 2024 |
| Barclays | Jiong Shao | $104 | $92.92 | -19.8% | Jun 13, 2024 |
| CFRA | Ahmad Halim | $130 | $94.74 | +0.3% | May 24, 2024 |
| Jefferies | Thomas Chong | $129 | $94.74 | -0.5% | May 23, 2024 |
| Morgan Stanley | Alex Poon | $120 | $97.15 | -7.4% | Apr 12, 2024 |
| Jefferies | Thomas Chong | $133 | $98.71 | +2.6% | Apr 2, 2024 |
| Morgan Stanley | Alex Poon | $135 | $98.71 | +4.1% | Apr 2, 2024 |
| Bernstein | Robin Zhu | $120 | $86.85 | -7.4% | Jun 5, 2023 |
| Citigroup | Analyst unavailable | $140 | $86.11 | +8.0% | Aug 19, 2022 |
| Macquarie | Esme Pau | $129 | $89.78 | -0.5% | Jul 13, 2022 |
| HSBC | Analyst unavailable | $122 | $97.49 | -5.9% | May 25, 2022 |
| CMB International Securities | Sophie Huang | $123 | $82.63 | -5.1% | Oct 5, 2021 |
| UOB Kay Hian | Julia Pan | $110 | $117.68 | -15.2% | May 20, 2021 |
| Macquarie | Han Joon Kim | $118 | $108.97 | -9.0% | May 19, 2021 |
Track every rating change on NTES the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationNetEase, Inc., a prominent technology firm founded in 1997 and headquartered in Hangzhou, People's Republic of China, delivers a broad spectrum of online services both within China and across international markets. Its core operations encompass online gaming, music streaming, intelligent online learning solutions, and diverse internet content services. The company organizes its activities into several key divisions: Games and Related Value-Added Services; Youdao, focusing on educational technology; Cloud Music for its audio streaming offerings; and a segment for Innovative Businesses and Others. Within its gaming division, NetEase is responsible for creating and managing both PC and mobile games, and it also publishes titles licensed from external game developers. The Youdao segment provides a comprehensive suite of online learning and translation tools, including Youdao Dictionary, Youdao Translation, U-Dictionary, and Youdao Kids' Dictionary.…
Historical context
All NTES earningsTechnology peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| KSPI Joint Stock Company Kaspi.kz | FY2026 Q3 · Calendar Q4 2026 | +0.6% | -2.4% | Kaspi.kz Lowers GMV Outlook as AI and Grocery Expand |
| TTWO Take-Two Interactive Software, Inc. | FY2027 Q2 · Calendar Q4 2026 | -69.9% | -3.5% | Take-Two holds its FY2027 outlook as GTA VI looms, despite a bookings shortfall |
| NVMI Nova Ltd. | FY2026 Q3 · Calendar Q4 2026 | +3.2% | -5.1% | Nova’s record Q3 reflects broad metrology demand; supply and adoption remain key tests |
| VSAT Viasat, Inc. | FY2027 Q2 · Calendar Q4 2026 | +23.9% | +7.7% | Viasat shifts toward ViaSat-3 monetization as DAT momentum offsets flat services |
| MCHPP Microchip Technology Incorporated | FY2027 Q2 · Calendar Q4 2026 | +3.6% | -13.1% | Microchip beat Q2 guidance, but supply constraints temper near-term outlook |
| QNT Quantinuum Inc. Class A Common Stock | FY2026 Q3 · Calendar Q4 2026 | +22.6% | +26.0% | Quantinuum Raises 2026 Outlook as Revenue Grows 233% |
Latest beats and misses
Who reports nextBeat on EPS
- NRGFY2026 Q3 · November 9, 2026+39.7% EPS+10.3% move
- FERGFY2026 Q3 · November 9, 2026+3.6% EPS+11.2% move
- KSPIFY2026 Q3 · November 9, 2026+0.6% EPS-2.4% move
- CEGFY2026 Q3 · November 9, 2026+29.7% EPS+10.5% move
- IXFY2027 Q2 · November 9, 2026+115.5% EPS-2.1% move
- TTDFY2026 Q3 · November 9, 2026+783.5% EPS+15.5% move
Missed on EPS
- TTWOFY2027 Q2 · November 9, 2026-69.9% EPS-3.5% move
- EMAFY2026 Q3 · November 6, 2026-3.7% EPS-1.0% move
- AHRFY2026 Q3 · November 5, 2026-9.0% EPS+3.3% move
- TUFY2026 Q3 · November 6, 2026-8.0% EPS-3.3% move
- PAAFY2026 Q3 · November 6, 2026-109.7% EPS-2.5% move
- CHTRFY2026 Q3 · November 6, 2026-330.3% EPS-6.2% move
Get the NTES recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-06T18:40:45.533775+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-06T18:40:45.531047+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-06. For educational purposes only; not investment advice.